Dr Reddy's Q2 Results: Profit Falls 36%, Is Recovery Ahead?

Dr Reddy's Laboratories reported a 36% year-on-year decline in net profit to ₹925 crore in Q2 FY27, while revenue fell 1.5% to ₹8,671 crore. The decline was largely driven by weaker sales of a key cancer drug in North America.

However, the company's underlying business continued growing, while profits more than doubled compared with the previous quarter.

So, is Dr Reddy's business actually weakening, or is the company gradually recovering from its dependence on a highly profitable US drug?

Dr Reddy's Q2 FY27 Results: Revenue, Profit and Margins

Dr Reddy's reported a mixed quarter, with revenue holding relatively steady but profitability declining significantly compared with last year.

The biggest concern is the difference between revenue and profit growth.

While revenue declined only 1.5%, EBITDA fell 24%, and net profit dropped 36%. This indicates that Dr Reddy's is not just experiencing weaker sales but is also earning considerably less profit from its existing revenue.

Its EBITDA margin declined from 26.7% to 20.6%. In simple terms, the company generated approximately ₹20.60 in operating earnings for every ₹100 of revenue, compared with ₹26.70 a year earlier.

However, the sequential comparison tells a more encouraging story.

Revenue increased 7.4% from Q1 FY27, while net profit jumped 109%. EBITDA margin also recovered from 12.5% to 20.6%.

This improvement is important, although the previous quarter was affected by a ₹240 crore provision related to semaglutide's active pharmaceutical ingredient (API). Consequently, part of the recovery came from the absence of that earlier expense.

For investors, the real question is whether Dr Reddy's can maintain this margin recovery in the coming quarters.

Why Did Dr Reddy's Profit Fall 36%? The North America Problem

The biggest reason behind the earnings decline was Dr Reddy's North American business.

North America generated ₹2,489 crore in Q2 FY27, compared with ₹3,241 crore in the same quarter last year. That represents a revenue decline of approximately 23%.

The main reason was lower sales of lenalidomide, a generic version of Revlimid, which is used to treat certain cancers.

Lenalidomide had been an important contributor to Dr Reddy's US business. However, as its sales contribution declined, the company lost a significant source of revenue and profitability. This explains why overall profits fell much faster than revenue.

How Significant Was the North American Decline?

North American revenue declined by approximately ₹752 crore year-on-year. Meanwhile, the company's total revenue declined by only ₹134 crore.

This means growth in other businesses offset a substantial portion of the weakness in North America.

In fact, excluding North American lenalidomide sales, Dr Reddy's reported double-digit growth in its underlying business.

This distinction is important because it suggests that the company's broader operations are continuing to expand even as a major historical profit contributor weakens.

However, there is another challenge. Replacing lenalidomide revenue does not automatically mean replacing its profitability. Newer products may face different pricing, manufacturing and marketing costs.

Therefore, the bigger challenge for Dr Reddy's is not simply replacing lost US sales but finding new businesses capable of generating comparable profits.

India and Emerging Markets Are Becoming Important Growth Drivers

While North America remained under pressure, Dr Reddy's other major markets delivered strong growth. India revenue increased 17% year-on-year to ₹1,851 crore, supported by the company's domestic pharmaceutical business.

Emerging markets performed even better, with revenue rising 24% to approximately ₹2,060 crore.

Together, India and emerging markets generated around ₹3,910 crore in quarterly revenue, accounting for roughly 45% of Dr Reddy's total revenue.

Europe, meanwhile, recorded modest growth of approximately 1%.

The company's pharmaceutical services and active ingredients business remained under pressure, with revenue declining 12%.

Dr Reddy's Margins Are Recovering, But Have Not Returned to Previous Levels

One of the most interesting aspects of Dr Reddy's Q2 results is its margin recovery. EBITDA margin improved from 12.5% in Q1 FY27 to 20.6% in Q2 FY27, an improvement of approximately 8.1 percentage points.

Gross margin also recovered from 46.5% to 52.1% during the same period. This indicates that profitability improved significantly compared with the previous quarter.

However, the year-on-year comparison remains weaker. Dr Reddy's reported an EBITDA margin of 26.7% in Q2 FY26, considerably higher than the latest 20.6%.

The difference highlights how much profitability has changed as the revenue contribution from lenalidomide declined.

The company also reported selling, general and administrative expenses of approximately ₹2,808 crore, an increase of 6% year-on-year despite lower revenue.

These costs accounted for 32.4% of revenue, compared with 30% a year earlier.

This means operating expenses absorbed a larger share of sales, putting additional pressure on profitability.

Research and development expenditure, meanwhile, declined 16% year-on-year to approximately ₹524 crore.

For investors, the margin recovery is encouraging, but it is too early to conclude that profitability has fully normalised.

Dr Reddy's must demonstrate that it can sustain margins through growth in its regular businesses rather than relying on unusually profitable individual products.

Can Semaglutide Become Dr Reddy's Next Major Growth Driver?

As the contribution from lenalidomide declines, attention is shifting towards Dr Reddy's upcoming products, particularly generic semaglutide.

Semaglutide is used to treat type 2 diabetes and is also associated with weight-management treatments, depending on the product and its regulatory approval.

This represents an important opportunity because demand for these treatments has increased globally.

Dr Reddy's has already secured generic semaglutide approvals in India, Canada and 10 countries across Latin America, Africa and the Middle East.

However, regulatory approval does not automatically translate into immediate revenue growth.

The company has also faced a quality issue involving certain batches of semaglutide API, which led to the ₹240 crore provision in Q1 FY27.

Management has targeted a November 2026 relaunch, subject to completing the necessary validation processes. This makes the upcoming quarters important.

Successful execution could help Dr Reddy's develop another growth driver. However, delays, competition and pricing pressure could affect how quickly semaglutide begins contributing meaningfully to earnings.

More importantly, semaglutide's revenue potential should not be confused with guaranteed profitability.

The business will need to demonstrate sustainable demand, competitive pricing and reliable manufacturing before investors can assess its long-term contribution.

Apart from semaglutide, Dr Reddy's is also expanding through biosimilars and partnerships, including a planned India launch of Takeda's dengue vaccine, QDENGA, in the private market in the first half of calendar year 2027.

These initiatives could support future growth, although their financial contribution will depend on commercial execution.

What Should Dr Reddy's Investors Watch After Q2 Results?

The latest results suggest that Dr Reddy's is making progress in its underlying operations, but several important questions remain unanswered.

First, can the company maintain EBITDA margins above 20%? Margins recovered sharply compared with Q1 but remained considerably below last year's levels. Sustained improvement would indicate that the business is adjusting to lower lenalidomide profitability.

Second, can India and emerging markets maintain double-digit growth? These businesses are becoming increasingly important for Dr Reddy's overall revenue. Their growth and profitability will influence how quickly the company can reduce its dependence on North America.

Third, how quickly can semaglutide contribute to earnings? Successful commercial execution could support future growth, but investors need to distinguish product approvals from actual sales and profit contributions.

Fourth, can new product launches offset the decline in US lenalidomide sales? This is arguably the biggest long-term earnings question. Revenue diversification is already visible, but replacing high-margin profits could take longer.

Investors should also watch the company's manufacturing compliance updates. Dr Reddy's disclosed regulatory observations at certain facilities and its responses to them. Resolving these matters remains important for product launches and business continuity.

Dr Reddy's Q2 Results: Is the Worst Over for Investors?

Dr Reddy's Q2 FY27 results present two contrasting trends.

On one hand, reported net profit declined 36%, North American revenue fell 23%, and operating margins remained considerably below last year's levels.

On the other hand, the company's underlying business continued growing, India and emerging markets delivered strong revenue growth, and quarterly profitability improved significantly from Q1.

This suggests that Dr Reddy's is going through an important earnings transition rather than experiencing weakness across all its businesses.

The company is moving away from the substantial contribution of lenalidomide towards a broader portfolio of branded medicines, generics, biosimilars and newer treatment opportunities.

However, this transition comes with a challenge. Growing revenue is relatively easier to demonstrate than replacing the profits generated by a highly successful drug.

For investors, the next phase will be determined by whether Dr Reddy's can consistently deliver operating margins above 20%, sustain growth in its core markets and successfully commercialise products such as semaglutide.

The latest quarter provides evidence of a recovery from Q1, but not yet a complete recovery in earnings.

The key takeaway is that Dr Reddy's underlying business is growing, but its future share-price performance will depend on how effectively that growth translates into sustainable profits.